8-K: Palatin Technologies Secures $18.2M in Upsized Public Offering

Palatin Technologies announced the closing of its $18.2 million public offering, including the full exercise of the over-allotment option, and regained NYSE American listing compliance.

Summary

• Palatin Technologies, Inc. closed its previously announced underwritten public offering, which included the full exercise of the underwriters' over-allotment option.
• The offering resulted in total gross proceeds of approximately $18.2 million, before deducting underwriting discounts, commissions, and offering expenses.
• The over-allotment option exercise alone generated additional gross proceeds of approximately $2.37 million.
• The offering included 2,795,384 shares of common stock (or pre-funded warrants), Series J warrants to purchase up to 2,795,384 shares, and Series K warrants to purchase up to 2,795,384 shares, at a combined public offering price of $6.50 per share.
• Net proceeds from the offering are intended to support the Company's obesity program development, working capital, and general corporate purposes.
• This closing enabled Palatin Technologies to regain compliance with the NYSE American continued listing standard under Section 1003(a)(iii) (Stockholders Equity Rule).
• Trading of the Company's common stock resumed on the NYSE American exchange under the symbol PTN on November 12, 2025.

Sentiment

Score: 8

Explanation: The successful closing of an upsized public offering, including the full exercise of the over-allotment option, demonstrates strong market interest and provides substantial capital. Crucially, regaining NYSE American listing compliance removes a significant overhang and stabilizes the Company's market position. The participation of institutional investors and insiders further bolsters confidence.

Positives

• Successfully closed an underwritten public offering, raising approximately $18.2 million in gross proceeds.
• The underwriters fully exercised their over-allotment option, indicating strong demand for the offering.
• The offering included participation from healthcare-focused, high-quality institutional investors, as well as the Company's CEO, CFO/COO, and certain board members.
• Regained compliance with the NYSE American continued listing standard (Stockholders Equity Rule), removing a significant delisting risk.
• Common stock resumed trading on the NYSE American exchange.
• Potential for an additional $18.2 million in proceeds upon cash exercise of Series J Warrants.

Negatives

• There is no guarantee that the Series J Warrants will be exercised, meaning the Company may not receive the potential additional $18.2 million in proceeds.

Risks

• The potential exercise of the milestone-related Series J Warrants may never occur, meaning the Company may not receive the additional $18.2 million in proceeds.
• Potential consequences due to the Company's reliance on Section 8(a) of the Securities Act, possibly related to a federal government shutdown.
• Market and other conditions could impact the Company's operations and financial performance.
• Uncertainty regarding the results of clinical trials for its product candidates.
• Regulatory actions by the FDA and other regulatory bodies, and the need for regulatory approvals.
• Palatin's ability to fund the development of its technology and successfully complete clinical trials.
• The length of time and cost required to complete clinical trials and submit applications for regulatory approvals.
• Competition from products developed by competing pharmaceutical, biopharmaceutical, and biotechnology companies.
• Uncertainty regarding commercial acceptance of Palatin's products.

Future Outlook

The Company intends to use the net proceeds from the offering to support the development of its obesity program and for working capital and general corporate purposes. There is a potential for up to an additional $18.2 million in proceeds if the Series J Warrants are exercised, though there is no guarantee of such exercise.

Management Comments

• Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters Over-Allotment Option.
• Trading of Palatin's common shares resumed trading on NYSE today, November 12, 2025, under the symbol PTN.

Industry Context

This capital raise positions Palatin Technologies, a biopharmaceutical company focused on melanocortin receptor system modulation, to advance its obesity program. In the biopharmaceutical sector, securing funding through public offerings is a common strategy to finance costly research and development, particularly for clinical-stage assets. The participation of healthcare-focused institutional investors suggests a degree of confidence in Palatin's pipeline and strategic direction, aligning with broader industry trends of specialized investment in promising therapeutic areas.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for a detailed assessment against global benchmarks.
• The participation of "healthcare-focused, high-quality institutional investors" suggests a positive reception within the specialized investment community for biopharmaceutical companies.
• Regaining compliance with NYSE American listing standards is a critical step for any publicly traded company, aligning with fundamental corporate governance and market access expectations.

Corporate Governance

Stakeholder Impact

• Shareholders: Existing shareholders face dilution from the issuance of new shares and warrants, but benefit from the Company's strengthened financial position, reduced delisting risk, and continued funding for its development programs. Potential for future value creation if the obesity program is successful.
• Employees: Enhanced job security and stability due to improved financial health and continued funding for research and development.
• Customers (future): Continued development of the obesity program could lead to new therapeutic options.
• Creditors: Improved financial stability and liquidity may reduce credit risk.

Next Steps

• Use net proceeds to support the development of the obesity program.
• Utilize net proceeds for working capital and general corporate purposes.
• Potential future exercise of Series J Warrants, which could provide additional capital.

Key Dates

Recommendation

The successful capital raise and regaining of NYSE compliance are significant positive developments, removing immediate financial and listing uncertainties. This provides a stable foundation for Palatin to advance its obesity program. However, as a biopharmaceutical company, future success heavily depends on clinical trial outcomes, regulatory approvals, and market acceptance, which remain inherently risky and uncertain. Therefore, a 'hold' recommendation is appropriate for investors who are already positioned, acknowledging the improved stability while awaiting further clinical and commercial progress.

Keywords

Palatin Technologies, PTN, Public Offering, Over-Allotment Option, Common Stock, Pre-Funded Warrants, Series J Warrants, Series K Warrants, NYSE American, Listing Compliance, Biopharmaceutical, Obesity Program, Capital Raise, SEC Filing, 8-K